Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance
Isocitrate dehydrogenase wild-type glioblastoma, a Grade 4 malignant brain neoplasm, remains resistant to multimodal treatment, with a median survival of 16 months from diagnosis with no geographical bias. Despite increasing appreciation of intra-tumour genotypic variation and stem cell plasticity,...
Saved in:
| Main Authors: | Pulkit Malhotra, Ruman Rahman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Onco |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-7523/4/4/24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unravelling the mosaic: Epigenetic diversity in glioblastoma
by: Sara Lucchini, et al.
Published: (2024-12-01) -
Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research
by: Hyunji Jo, et al.
Published: (2024-11-01) -
Tumour heterogeneity and personalized treatment screening based on single-cell transcriptomics
by: Xinying Zhang, et al.
Published: (2025-01-01) -
NOT THE USUAL SUSPECTS: GLIOBLASTOMA OF THE CEREBELLOPONTINE ANGLE MASQUERADING AS A VESTIBULAR SCHWANNOMA
by: Vlad Adrian Padurean, et al.
Published: (2024-11-01) -
The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?
by: Francesco Spallotta, et al.
Published: (2024-11-01)